Legend Biotech (LEGN) CEO Ying Huang makes charitable gift of 3,382 shares

Rhea-AI Filing Summary

Legend Biotech Corp director and CEO Ying Huang reported a charitable stock gift. On this Form 4, Huang made a bona fide gift transfer of 3,382 Ordinary Shares of Legend Biotech Corp to a charitable organization, receiving no cash consideration.

After the gift, Huang directly owns 238,490 Ordinary Shares. The company notes that its Ordinary Shares may be represented by American Depositary Shares, with each ADS representing two Ordinary Shares.

Insider Trade Summary

3,382 shares gifted

Mixed 1 txn

Insider Huang Ying

Role Chief Executive Officer

Type	Security	Shares	Price	Value
Gift	Ordinary Shares	3,382	$0.00	--

Holdings After Transaction: Ordinary Shares — 238,490 shares (Direct, null)

Footnotes (1)

1. The Ordinary Shares of the Issuer may be represented by American Depositary Shares ("ADSs"). Each ADS represents two ordinary shares of the Issuer. Represents a bone fide gift to a charitable organization.

Key Figures

Shares gifted: 3,382 Ordinary Shares Shares held after transaction: 238,490 Ordinary Shares ADS to Ordinary Share ratio: 1 ADS = 2 Ordinary Shares

3 metrics

Shares gifted 3,382 Ordinary Shares Bona fide gift to a charitable organization

Shares held after transaction 238,490 Ordinary Shares Direct ownership following gift disposition

ADS to Ordinary Share ratio 1 ADS = 2 Ordinary Shares Representation of Ordinary Shares by ADSs

Key Terms

bona fide gift, American Depositary Shares, Ordinary Shares

3 terms

bona fide gift financial

"Represents a bone fide gift to a charitable organization."

A bona fide gift is a genuine, voluntary transfer of money, property, or benefits from one party to another made without expectation of repayment, services, or hidden conditions. Investors care because such gifts can affect company disclosures, related‑party transaction rules, tax treatment, and perceived conflicts of interest; think of it like someone giving you a present with no strings attached — but on a corporate scale, auditors and regulators need to verify it really is unconditional.

American Depositary Shares financial

"The Ordinary Shares of the Issuer may be represented by American Depositary Shares ("ADSs")."

American depositary shares (ADSs) are a way for investors in the United States to buy shares of foreign companies without dealing with international markets directly. They represent ownership in a foreign company's stock and are traded on U.S. stock exchanges, making it easier for American investors to buy, sell, and own parts of companies from around the world.

Ordinary Shares financial

"The Ordinary Shares of the Issuer may be represented by American Depositary Shares ("ADSs")."

Ordinary shares are a type of ownership stake in a company, giving shareholders a right to participate in the company’s profits and decision-making through voting. They are similar to owning a piece of a business, and their value can rise or fall based on the company's performance. Investors buy ordinary shares to potentially earn dividends and benefit from the company's growth over time.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 07/02/2026 - 04:06 PM Accepted by SEC EDGAR 07/02/2026 - 04:05 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Huang Ying

(Last) (First) (Middle)

C/O LEGEND BIOTECH CORP

2101 COTTONTAIL LANE

(Street)

SOMERSET NEW JERSEY 08873

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Legend Biotech Corp [ LEGN ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Executive Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/30/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Ordinary Shares(1)	06/30/2026		G(2)		3,382	D	$0	238,490	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The Ordinary Shares of the Issuer may be represented by American Depositary Shares ("ADSs"). Each ADS represents two ordinary shares of the Issuer.

2. Represents a bone fide gift to a charitable organization.

	/s/ James Pepin, Attorney-in-Fact	07/02/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did Legend Biotech (LEGN) report in this Form 4?

Legend Biotech reported that CEO and director Ying Huang made a bona fide gift of 3,382 Ordinary Shares. The transfer was to a charitable organization and involved no sale proceeds, indicating a non-market, charitable disposition of stock rather than an open-market transaction.

How many Legend Biotech (LEGN) shares does Ying Huang hold after the reported gift?

After the reported gift, Ying Huang directly holds 238,490 Ordinary Shares of Legend Biotech. This post-transaction ownership figure comes from the Form 4 and shows Huang retains a substantial equity position following the charitable transfer of 3,382 shares.

Was cash involved in Ying Huang’s Form 4 transaction for Legend Biotech (LEGN)?

No cash was involved in the Form 4 transaction. The filing classifies the event as a bona fide gift of 3,382 Ordinary Shares at a reported price of $0.00 per share, reflecting a charitable transfer rather than a purchase or sale in the market.

How are Legend Biotech (LEGN) Ordinary Shares related to its American Depositary Shares (ADSs)?

Legend Biotech states that its Ordinary Shares may be represented by American Depositary Shares. Each ADS represents two Ordinary Shares, meaning ADR investors indirectly hold the underlying Ordinary Shares through this 2-to-1 share relationship disclosed in the Form 4 footnote.

Is the Legend Biotech (LEGN) Form 4 transaction a buy or sell by Ying Huang?

The Form 4 transaction is neither a buy nor a market sale. It is coded as a bona fide gift, described as a gift transfer of 3,382 Ordinary Shares to a charitable organization, so it represents a non-market disposition rather than trading activity by Ying Huang.